Teva to pay $512m to settle Provigil class action
This article was originally published in Scrip
Executive Summary
Teva has agreed to pay $512m to settle a class-action lawsuit in which direct purchasing firms asserted Cephalon, which the Israeli company acquired in 2011, paid generic competitors in 2008 more than $200m to keep cheaper versions of the narcolepsy and sleep apnea drug Provigil (modafinil) off the US market.